Your Questions Answered About Coronavirus (COVID-19)

An Ohio State hematologist discusses a new trial comparing tovorafenib plus rituximab with standard cladribine-based treatment, and what quality of life means for patients.

An Ohio State hematologist explains how she weighs chemotherapy against targeted drugs, what side effects patients should expect and why learning about this specific leukemia matters.

Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.

Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.

Treatment for stomach cancer depends mostly on its stage and, for advanced disease, on biomarkers such as HER2. This Stomach Cancer Awareness Month explainer walks through the main options at each stage, based on National Cancer Institute guidance.

A mother whose daughter is seven years past breast cancer treatment shares how scan anxiety and waiting shape life after cancer for survivors and families.

A review of 29 studies in more than 22,000 women 65 and older with ER-positive breast cancer found no statistically significant survival difference between hormone therapy alone and surgery first, though surgery controlled the cancer in the breast better.

The FDA approved Imfinzi plus Padcev before and after surgery for adults with muscle-invasive bladder cancer who cannot or will not receive cisplatin.